Rifaximin oral tablet (DrugBank: Rifaximin)
7 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 0 |
65 | 原発性免疫不全症候群 | 0 |
94 | 原発性硬化性胆管炎 | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
99 | 慢性特発性偽性腸閉塞症 | 1 |
296 | 胆道閉鎖症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04118699 (ClinicalTrials.gov) | December 25, 2019 | 23/9/2019 | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial | Chronic Intestinal Pseudo-obstruction | Drug: Rifaximin oral tablet;Drug: Placebo oral tablet | Yokohama City University | ASKA Pharmaceutical Co., Ltd. | Recruiting | 20 Years | 74 Years | All | 12 | Phase 2 | Japan |